thalidomide has been researched along with Hand-Schu00FCller-Christian Disease in 34 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease." | 8.88 | [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012) |
| "We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease." | 4.88 | [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012) |
| " Thalidomide (N-phtalimidoglutarimide), initially used as a tranquilizer, has recently been used in the management of several inflammatory skin diseases." | 3.72 | Successful treatment of cutaneous langerhans cell histiocytosis with thalidomide. ( Elsner, P; Kaatz, M; Sander, CS, 2004) |
| "Thalidomide is an effective therapy for some LR patients with LCH, but showed no significant responses in HR patients." | 2.73 | A phase II trial using thalidomide for Langerhans cell histiocytosis. ( Kozinetz, CA; McClain, KL, 2007) |
| "Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects." | 2.43 | Thalidomide: dermatological indications, mechanisms of action and side-effects. ( Hsu, S; Huang, DB; Pang, KR; Tyring, SK; Wu, JJ, 2005) |
| "Thalidomide has proven useful for patients with Langerhans cell histiocytosis of the skin and/or bone." | 2.43 | Drug therapy for the treatment of Langerhans cell histiocytosis. ( McClain, KL, 2005) |
| " All four children completed the protocol without any significant adverse effects and remain in complete and durable remission 15-18 months posttreatment." | 1.46 | Excellent remission rates with limited toxicity in relapsed/refractory Langerhans cell histiocytosis with pulse dexamethasone and lenalidomide in children. ( Bakane, A; Raj, R; Ramachandrakurup, S; Subburaj, D; Uppuluri, R, 2017) |
| "Refractory/relapsed Langerhans cell histiocytosis (LCH) has a difficult course with a guarded prognosis." | 1.46 | Successful Treatment of Refractory Langerhans Cell Histiocytosis of the Choroid Plexus in a Child With Pulse Dexamethasone and Lenalidomide. ( Bakane, A; Balaji, R; Raj, R; Ramachandrakurup, S; Subburaj, D; Uppuluri, R, 2017) |
| "Adult Langerhans cell histiocytosis (LCH) usually follows a favorable course." | 1.38 | [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp ( Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012) |
| "Thalidomide is an immunomodulator agent of inflammatory cytokines including TNF-alpha." | 1.33 | A case of disseminated Langerhans' cell histiocytosis treated with thalidomide. ( Castoldi, G; Fraulini, C; Galeotti, R; Mauro, E; Rigolin, GM; Spanedda, R, 2005) |
| "Thalidomide treatment is an adequate therapeutic measure in adult Langerhans cell histiocytosis, which is rare and difficult to treat." | 1.33 | [Thalidomide in adult multisystem Langerhans cell histiocytosis: a case report]. ( Alioua, Z; Frikh, R; Ghfir, M; Hjira, N; Oumakhir, S; Rimani, M; Sedrati, O, 2006) |
| "Adult onset Langerhans cell histiocytosis is uncommon." | 1.31 | Langerhans' cell histiocytosis. ( Ehsani, A; Hosseini, M; Mortazavi, H; Namazi, MR, 2002) |
| "We report one case of Langerhans cell histiocytosis in a 33-year-old woman with resistant vulvar involvement whose cutaneous lesions improved with thalidomide." | 1.30 | [Langerhans histiocytosis in adults: cutaneous and mucous lesion regression after treatment with thalidomide]. ( Blot, E; Boullié, MC; Cailleux, N; Courtois, H; Courville, P; Lair, G; Lauret, P; Lévesque, H; Marie, I, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (17.65) | 18.2507 |
| 2000's | 15 (44.12) | 29.6817 |
| 2010's | 12 (35.29) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, JN | 1 |
| Liu, T | 1 |
| Zhao, AL | 1 |
| Pan, BJ | 1 |
| Sun, J | 1 |
| Li, J | 1 |
| Zhou, DB | 1 |
| Cao, XX | 1 |
| Duan, MH | 1 |
| Roider, E | 1 |
| Signer, C | 1 |
| Fehrenbacher, B | 1 |
| Metzler, G | 2 |
| Schaller, M | 2 |
| Kamarachev, J | 1 |
| Kerl, K | 1 |
| Balabanov, S | 1 |
| Jochum, W | 1 |
| Hoetzenecker, W | 1 |
| Cozzio, A | 1 |
| French, LE | 1 |
| Dummer, R | 1 |
| Guenova, E | 1 |
| Minkov, M | 1 |
| Wu, C | 1 |
| Uppuluri, R | 2 |
| Ramachandrakurup, S | 2 |
| Subburaj, D | 2 |
| Bakane, A | 2 |
| Raj, R | 2 |
| Ruiz Beguerie, J | 1 |
| Fernández, J | 1 |
| Stringa, MF | 1 |
| Anaya, J | 1 |
| Balaji, R | 1 |
| Ng-Cheng-Hin, B | 1 |
| O'Hanlon-Brown, C | 1 |
| Alifrangis, C | 1 |
| Waxman, J | 1 |
| Szturz, P | 3 |
| Adam, Z | 3 |
| Rehák, Z | 3 |
| Koukalová, R | 3 |
| Slaisová, R | 1 |
| Stehlíková, O | 1 |
| Chovancová, J | 1 |
| Klabusay, M | 1 |
| Krejčí, M | 3 |
| Pour, L | 3 |
| Hájek, R | 3 |
| Mayer, J | 3 |
| Zahradová, L | 2 |
| Moulis, M | 1 |
| Kodet, R | 1 |
| Nebeský, T | 2 |
| Brejcha, M | 1 |
| Adamová, Z | 1 |
| Alexandrescu, S | 1 |
| Tatevian, N | 1 |
| Czerniak, BA | 1 |
| Covinsky, MH | 1 |
| Burns, NK | 1 |
| Brown, RE | 1 |
| Král, Z | 1 |
| Li, KY | 1 |
| Hu, YM | 1 |
| Lü, JB | 1 |
| Claudon, A | 1 |
| Dietemann, JL | 1 |
| Hamman De Compte, A | 1 |
| Hassler, P | 1 |
| Kolde, G | 1 |
| Schulze, P | 1 |
| Sterry, W | 1 |
| Mortazavi, H | 1 |
| Ehsani, A | 1 |
| Namazi, MR | 1 |
| Hosseini, M | 1 |
| Santillan, A | 1 |
| Montero, AJ | 1 |
| Kavanagh, JJ | 1 |
| Liu, J | 1 |
| Ramirez, PT | 1 |
| Deng, YJ | 1 |
| Hao, F | 1 |
| Zhou, CL | 1 |
| Sun, RS | 1 |
| Xiang, MM | 1 |
| Wang, JW | 1 |
| Zhong, BY | 1 |
| Ye, QY | 1 |
| Liu, RQ | 1 |
| Sander, CS | 1 |
| Kaatz, M | 1 |
| Elsner, P | 1 |
| Mauro, E | 1 |
| Fraulini, C | 1 |
| Rigolin, GM | 1 |
| Galeotti, R | 1 |
| Spanedda, R | 1 |
| Castoldi, G | 1 |
| Wu, JJ | 1 |
| Huang, DB | 1 |
| Pang, KR | 1 |
| Hsu, S | 1 |
| Tyring, SK | 1 |
| McClain, KL | 2 |
| Kozinetz, CA | 1 |
| Alioua, Z | 1 |
| Hjira, N | 1 |
| Oumakhir, S | 1 |
| Frikh, R | 1 |
| Ghfir, M | 1 |
| Rimani, M | 1 |
| Sedrati, O | 1 |
| Moravvej, H | 1 |
| Yousefi, M | 1 |
| Barikbin, B | 1 |
| Broekaert, SM | 1 |
| Burgdorf, W | 1 |
| Röcken, M | 1 |
| Dallafior, S | 1 |
| Pugin, P | 1 |
| Cerny, T | 1 |
| Betticher, D | 1 |
| Saurat, JH | 1 |
| Hauser, C | 1 |
| Meunier, L | 1 |
| Marck, Y | 1 |
| Ribeyre, C | 1 |
| Meynadier, J | 1 |
| Thomas, L | 1 |
| Ducros, B | 1 |
| Secchi, T | 1 |
| Balme, B | 1 |
| Moulin, G | 1 |
| Misery, L | 1 |
| Larbre, B | 1 |
| Lyonnet, S | 1 |
| Faure, M | 1 |
| Thivolet, J | 1 |
| Lair, G | 1 |
| Marie, I | 1 |
| Cailleux, N | 1 |
| Blot, E | 1 |
| Boullié, MC | 1 |
| Courville, P | 1 |
| Lauret, P | 1 |
| Lévesque, H | 1 |
| Courtois, H | 1 |
| Moraes, M | 1 |
| Russo, G | 1 |
| Pouaha, J | 1 |
| Martin, S | 1 |
| Trechot, P | 1 |
| Truchetet, F | 1 |
| Barbaud, A | 1 |
| Schmutz, JL | 1 |
| Bensaid, P | 1 |
| Machet, L | 1 |
| Vaillant, L | 1 |
| Machet, MC | 1 |
| Scotto, B | 1 |
| Lorette, G | 1 |
9 reviews available for thalidomide and Hand-Schu00FCller-Christian Disease
| Article | Year |
|---|---|
An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy.
Topics: Antineoplastic Agents; Central Nervous System; Child; Clinical Trials as Topic; Drug Therapy, Combin | 2018 |
Langerhans cell histiocytosis: old disease new treatment.
Topics: Cladribine; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Thalidomide | 2011 |
[The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis].
Topics: Aged; Castleman Disease; Erdheim-Chester Disease; Female; Histiocytosis, Langerhans-Cell; Humans; Le | 2012 |
Vulvar Langerhans cell histiocytosis: a case report and review of the literature.
Topics: Adult; Combined Modality Therapy; Female; Histiocytosis, Langerhans-Cell; Humans; Thalidomide; Vulva | 2003 |
Thalidomide: dermatological indications, mechanisms of action and side-effects.
Topics: Adult; Behcet Syndrome; Dermatologic Agents; Erythema; Graft vs Host Disease; Histiocytosis, Langerh | 2005 |
Drug therapy for the treatment of Langerhans cell histiocytosis.
Topics: Anti-Inflammatory Agents; Antimetabolites; Brain Diseases; Cell Proliferation; Cladribine; Cytarabin | 2005 |
Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review.
Topics: Adolescent; Anus Diseases; Female; Histiocytosis, Langerhans-Cell; Humans; Middle Aged; Skin; Thalid | 1993 |
Thalidomide and its dermatologic uses.
Topics: Acquired Immunodeficiency Syndrome; Behcet Syndrome; Dermatologic Agents; Erythema Nodosum; Facial D | 2001 |
[Langerhans-cell histiocytosis in the adult: regressive parotid involvement following thalidomide therapy].
Topics: Adult; Female; Histiocytosis, Langerhans-Cell; Humans; Intertrigo; Parotid Diseases; Pregnancy; Preg | 1992 |
2 trials available for thalidomide and Hand-Schu00FCller-Christian Disease
| Article | Year |
|---|---|
Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Histiocytosi | 2022 |
A phase II trial using thalidomide for Langerhans cell histiocytosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Disease-Free Survival; Female; Histiocytosis, Langerhans | 2007 |
23 other studies available for thalidomide and Hand-Schu00FCller-Christian Disease
| Article | Year |
|---|---|
Individualized treatment approaches for Langerhans cell histiocytosis.
Topics: Adrenal Cortex Hormones; Adult; Aged, 80 and over; Azetidines; Bone Diseases; Dermatologic Agents; F | 2018 |
Red plaques and tumors on the vulva.
Topics: Asymptomatic Diseases; Female; Glucocorticoids; Histiocytosis, Langerhans-Cell; Humans; Immunosuppre | 2019 |
Excellent remission rates with limited toxicity in relapsed/refractory Langerhans cell histiocytosis with pulse dexamethasone and lenalidomide in children.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Child, Preschool; Dexamethasone; Drug Resistance; | 2017 |
Vulvar Langerhans cell histiocytosis and thalidomide: an effective treatment option.
Topics: Female; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Middle Aged; Thalidomide; | 2017 |
Successful Treatment of Refractory Langerhans Cell Histiocytosis of the Choroid Plexus in a Child With Pulse Dexamethasone and Lenalidomide.
Topics: Choroid Plexus; Cladribine; Cytarabine; Dexamethasone; Diabetes Insipidus; Drug Resistance; Histiocy | 2017 |
Lenalidomide proved effective in multisystem Langerhans cell histiocytosis.
Topics: Adult; Antineoplastic Agents; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Neoplasm R | 2012 |
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality The | 2012 |
Morphoproteomics provides support for TGF-β pathway signaling in the osteoclastogenesis and immune dysregulation of osteolytic Langerhans cell histiocytosis.
Topics: Biomarkers; Cell Differentiation; Cell Membrane; Cell Nucleus; Child; Child, Preschool; Cytoplasm; F | 2012 |
[Six years relapse-free treatment of a case with Langerhans cell histiocytosis grade III treated with thalidomide and prednisone].
Topics: Administration, Oral; Adolescent; Female; Histiocytosis, Langerhans-Cell; Humans; Lymph Nodes; Predn | 2012 |
[Interest in thalidomide in cutaneo-mucous and hypothalamo-hypophyseal involvement of Langerhans cell histiocytosis].
Topics: Adult; Female; Genital Diseases, Female; Histiocytosis, Langerhans-Cell; Humans; Hypothalamic Diseas | 2002 |
Mixed response to thalidomide therapy in adults: two cases of multisystem Langerhans' cell histiocytosis.
Topics: Administration, Oral; Adult; Anus Diseases; Dose-Response Relationship, Drug; Drug Administration Sc | 2002 |
Langerhans' cell histiocytosis.
Topics: Adult; Histiocytosis, Langerhans-Cell; Humans; Male; Skin Diseases; Thalidomide | 2002 |
Generalized eruptive histiocytosis: a possible therapeutic cure?
Topics: Adult; Dermatologic Agents; Drug Therapy, Combination; Facial Dermatoses; Histiocytosis, Langerhans- | 2004 |
Successful treatment of cutaneous langerhans cell histiocytosis with thalidomide.
Topics: Administration, Oral; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration S | 2004 |
A case of disseminated Langerhans' cell histiocytosis treated with thalidomide.
Topics: Aged; Female; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Langerhans Cells; Th | 2005 |
[Thalidomide in adult multisystem Langerhans cell histiocytosis: a case report].
Topics: Adult; Female; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Remission Induction | 2006 |
An unusual case of adult disseminated cutaneous Langerhans cell histiocytosis.
Topics: Adult; Antigens, CD1; Biomarkers; Combined Modality Therapy; Cyclosporine; Histiocytosis, Langerhans | 2006 |
Multisystem Langerhans cell histiocytosis: successful treatment with thalidomide.
Topics: Anti-Inflammatory Agents; Central Nervous System Diseases; Female; Histiocytosis, Langerhans-Cell; H | 2007 |
[Successful treatment of a case of cutaneous Langerhans cell granulomatosis with 2-chlorodeoxyadenosine and thalidomide].
Topics: Aged; Cladribine; Drug Therapy, Combination; Female; Histiocytosis, Langerhans-Cell; Humans; Immunos | 1995 |
Adult cutaneous Langerhans cell histiocytosis: remission with thalidomide treatment.
Topics: Aged; Histiocytosis, Langerhans-Cell; Humans; Male; Skin Diseases; Thalidomide | 1995 |
Remission of Langerhans cell histiocytosis with thalidomide treatment.
Topics: Aged; Histiocytosis, Langerhans-Cell; Humans; Male; Thalidomide | 1993 |
[Langerhans histiocytosis in adults: cutaneous and mucous lesion regression after treatment with thalidomide].
Topics: Adult; Dermatologic Agents; Female; Histiocytosis, Langerhans-Cell; Humans; Patient Compliance; Recu | 1998 |
[Thalidomide and thrombosis: three observations].
Topics: Adult; Aged; Behcet Syndrome; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Lupu | 2001 |